BL Pharmtech Corp.

KOSDAQ:A065170 Stock Report

Market Cap: ₩50.9b

BL Pharmtech Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Hyo-Lim Lee

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Analysis Article • Jan 07

Is BL Pharmtech (KOSDAQ:065170) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Apr 02

BL Pharmtech (KOSDAQ:065170) Is Making Moderate Use Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Dec 18

Here's Why BL Pharmtech (KOSDAQ:065170) Can Afford Some Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Sep 03

BL Pharmtech (KOSDAQ:065170) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • May 21

Some Confidence Is Lacking In BL Pharmtech Corp.'s (KOSDAQ:065170) P/S

When you see that almost half of the companies in the Personal Products industry in Korea have price-to-sales ratios...
Analysis Article • Mar 07

Is BL Pharmtech (KOSDAQ:065170) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Mar 14

Reflecting on Next Bt's (KOSDAQ:065170) Share Price Returns Over The Last Three Years

As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...
Analysis Article • Jan 20

Does Next Bt (KOSDAQ:065170) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Nov 28

Next Bt's (KOSDAQ:065170) Shareholders Are Down 43% On Their Shares

The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have...

CEO

Hyo-Lim Lee

no data
Tenure

Mr. Hyo-Lim Lee serves as the Chief Executive Officer of BL Pharmtech Corp. (formerly known as NRD Co., Ltd.).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/31 03:56
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BL Pharmtech Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Taehyeong KimKB Securities Co., Ltd.